AP2015008919A0 - Nanoparticulate formulation comprising a trpa1 antagonist - Google Patents

Nanoparticulate formulation comprising a trpa1 antagonist

Info

Publication number
AP2015008919A0
AP2015008919A0 AP2015008919A AP2015008919A AP2015008919A0 AP 2015008919 A0 AP2015008919 A0 AP 2015008919A0 AP 2015008919 A AP2015008919 A AP 2015008919A AP 2015008919 A AP2015008919 A AP 2015008919A AP 2015008919 A0 AP2015008919 A0 AP 2015008919A0
Authority
AP
ARIPO
Prior art keywords
trpa1 antagonist
nanoparticulate formulation
nanoparticulate
formulation
trpa1
Prior art date
Application number
AP2015008919A
Other languages
English (en)
Inventor
Suresh Rajurkar
Nilesh Jain
Ulhas Dhuppad
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of AP2015008919A0 publication Critical patent/AP2015008919A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AP2015008919A 2013-06-20 2014-06-20 Nanoparticulate formulation comprising a trpa1 antagonist AP2015008919A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2090MU2013 2013-06-20
PCT/IB2014/062462 WO2014203210A1 (en) 2013-06-20 2014-06-20 Nanoparticulate formulation comprising a trpa1 antagonist

Publications (1)

Publication Number Publication Date
AP2015008919A0 true AP2015008919A0 (en) 2015-12-31

Family

ID=51136536

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008919A AP2015008919A0 (en) 2013-06-20 2014-06-20 Nanoparticulate formulation comprising a trpa1 antagonist

Country Status (13)

Country Link
US (1) US10603277B2 (xx)
EP (1) EP3010489A1 (xx)
JP (1) JP2016522251A (xx)
CN (1) CN105307642A (xx)
AP (1) AP2015008919A0 (xx)
AU (1) AU2014282762B2 (xx)
BR (1) BR112015030341A2 (xx)
CA (1) CA2912578A1 (xx)
EA (1) EA201592120A1 (xx)
HK (1) HK1221161A1 (xx)
MX (1) MX2015016024A (xx)
PH (1) PH12015502820A1 (xx)
WO (1) WO2014203210A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190175599A1 (en) * 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
PL3568122T3 (pl) * 2017-01-10 2024-03-18 Dukebox Sp. Z O.O. Sposób wytwarzania zawiesiny nanocząsteczek soli potasowej albo soli magnezowej
WO2020053609A1 (en) * 2018-09-11 2020-03-19 Lead Biotherapeutics Ltd. Mucoadhesive dispersion nanoparticle system and method for production the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IT1298575B1 (it) 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
UA76810C2 (uk) 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
AU2006225117A1 (en) * 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
US8575178B2 (en) 2009-03-23 2013-11-05 Glenmark Pharmaceuticals S.A. Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators
WO2010109329A1 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
US8829196B2 (en) 2009-10-07 2014-09-09 Merck Sharp & Dohme Corp. TRPA1 antagonists
WO2012176105A1 (en) * 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
CA2873570C (en) 2012-06-08 2016-11-01 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts as trpa1 modulators

Also Published As

Publication number Publication date
US10603277B2 (en) 2020-03-31
HK1221161A1 (zh) 2017-05-26
CA2912578A1 (en) 2014-12-24
AU2014282762B2 (en) 2016-11-10
JP2016522251A (ja) 2016-07-28
PH12015502820A1 (en) 2016-03-21
US20140377358A1 (en) 2014-12-25
CN105307642A (zh) 2016-02-03
WO2014203210A1 (en) 2014-12-24
MX2015016024A (es) 2016-04-04
BR112015030341A2 (pt) 2017-07-25
EP3010489A1 (en) 2016-04-27
EA201592120A1 (ru) 2016-04-29
AU2014282762A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
GB201306610D0 (en) Pharmaceutical compounds
ZA201602307B (en) A ball
HK1222547A1 (zh) 延遲釋放的藥物製劑
GB201317990D0 (en) A conncetor
GB2520939B (en) A Platform
HUP1300139A2 (en) Phenoxypiperidine h3 antagonists
RS58856B1 (sr) Nova stabilna formulacija
HK1221161A1 (zh) 包含 拮抗劑的納米顆粒製劑
PL3066091T3 (pl) Proleki antagonisty nmda
GB201322948D0 (en) Improved formulation
RS58123B1 (sr) Otpuštač mamca za ribe
IL246091A0 (en) Opioid antagonist formulations
GB2517232B (en) Formulation
AU346919S (en) A vial assembly
HK1209981A1 (en) Formulation
GB201311260D0 (en) Sizer
GB201321316D0 (en) Pharmaceutical Compound
GB201312347D0 (en) Formulation
GB201309405D0 (en) Pharmaceutical compound
GB201313909D0 (en) Powder formulation
GB201319398D0 (en) A footgauge
GB201322181D0 (en) Feed formulation
GB201304146D0 (en) Powder formulation
GB201304145D0 (en) Powder formulation
GB201321280D0 (en) Feed formulation